why choose us

First received: April 09, 2026

Clinical Trial: Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Esophageal Cancer

Study Type: OBSERVATIONAL


Official Title: Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis

Brief Summary: Taxane-based agents are widely used in the treatment of esophageal squamous cell carcinoma (ESCC).Among these, nab-paclitaxel (albumin-bound paclitaxel) and paclitaxel are the most commonly used.However, there is currently no definitive evidence comparing the efficacy of these two agents in the context of neoadjuvant therapy for ESCC.

Read more